-
Neoadjuvant Atezolizumab Plus Epirubicin Shows Safety, Efficacy in Treatment of HER2+ Early Breast Cancer
24 Jan 2025 18:47 GMT
… approved by the European Medicines Agency for the treatment of PD-L1 … -escalation immunotherapy regimen with trastuzumab (Herceptin; Genentech), pertuzumab (Perjeta; Genentech), … ;trial/2019-002364-27/AT
2. Drugs.com. Tecentriq FDA approval …
-
Dr Montero on Unmet Treatment Needs for HER2+ Metastatic Breast Cancer
23 Jan 2025 23:38 GMT
… currently approved HER2-targeted drugs stops working.”
Alberto Montero … University School of Medicine, discusses unmet treatment needs for … enrollment in this trial needed to have … prior regimens, including trastuzumab (Herceptin), pertuzumab (Perjeta), and …
-
Fosun's proposed Henlius Biotech buyout fails to pass shareholder vote
22 Jan 2025 23:34 GMT
… owned subsidiary, Shanghai Henlius Biotech, has been quashed, with … won FDA approval in September for its Accord-partnered Herceptin … cancer. The drug already boasts an orphan drug designation in … pivot to becoming an innovative drugmaker.
In its 2023 fiscal …
-
T-DM1 Shows Promise in HER2+ Biliary Tract Cancer
28 Jan 2025 23:28 GMT
… note, 15% were given trastuzumab (Herceptin) in the first line and … on first line treatment.
Patients were included in the trial if they … of grade 3/4 treatment-related adverse effects (AEs).
The … CI, 2.9-6.9).
Treatment-related AEs of grade 3 …
-
Camrelizumab Plus Chemo Yields Improved Response Rates in Gastric/GEJ Cancer
23 Jan 2025 23:48 GMT
… trial preliminarily shows promising results providing a new conversion drug treatment … from the Department of Medical Oncology, Fudan University … they were given trastuzumab (Herceptin) at 6 mg… disease.
Regarding safety, treatment-related adverse effects ( …
-
Inavolisib Plus Palbociclib/Fulvestrant Shows OS Benefit in Endocrine-Resistant, PIK3CA-Mutated, HR+, HER2– Breast Cancer
28 Jan 2025 17:16 GMT
… Medicines Agency.
INAVO120 Overview
The randomized, double-blind, placebo-controlled trial … subsequent cycle. Treatment continued until … and trastuzumab (Herceptin) as maintenance therapy … fda.gov/drugs/;resources-information-approved-drugs/fda- …
-
Tucatinib in Combination With Trastuzumab Demonstrates Safety, Efficacy in Patients With HER2-Mutated Breast Cancer
27 Jan 2025 15:42 GMT
… BioPharma) and trastuzumab (Herceptin; Genentech) demonstrated clinically meaningful … data from the HER2CLIMB trial (NCT02614794), where … profiles. As precision medicine advances, these results … mutations and tailoring treatment strategies to improve outcomes …
-
Dr Wainberg on the Phase 2/3 ASPEN-06 Study of Evorpacept in HER2-Overexpressing Gastric/GEJ Cancer
26 Jan 2025 00:53 GMT
… Oncology Program, and professor of medicine, UCLA Health, discusses findings from … -06 trial (NCT05002127) of evorpacept plus standard-of-care trastuzumab (Herceptin), ramucirumab …
-
Adjuvant Trastuzumab Emtansine Improves Invasive Disease-Free Survival in Patients with HER2+ Early Breast Cancer
24 Jan 2025 23:48 GMT
… IDFS) compared with trastuzumab (Herceptin; Genentech) alone in patients … of Medicine, are from the phase 3 KATHERINE trial ( … a HER2-targeted antibody drug conjugate composed of trastuzumab … received FDA approval in 2019 for the adjuvant treatment of …
-
Trastuzumab/Pertuzumab/Chemo Does Not Confer Response Advantage in Gastric/GEJ Cancer
24 Jan 2025 04:06 GMT
The addition of trastuzumab (Herceptin) and pertuzumab (Perjeta) to … NR across all 3 treatment arms in the overall … 2.66).
Before the trial amendment regarding the chemotherapy … investigators of the INNOVATION trial amended the protocol to incorporate …
About
© 1995-2025